News

Recursion Acquires Full Rights to REV102, a Potential First-in-Class Oral ENPP1 Inhibitor for Hypophosphatasia
Detailed price information for Recursion Pharmaceuticals Inc Cl A (RXRX-Q) from The Globe and Mail including charting and trades.
GEN - Genetic Engineering and Biotechnology News6d
RNA Expands Its Clinical Clout
No longer a mere assistant who carries out the commands of DNA, RNA takes the lead in emerging therapeutics.
Recursion Pharmaceuticals: Recursion Acquires Full Rights to REV102, a Potential First-in-Class Oral ENPP1 Inhibitor for Hypophosphatasia
Recursion (NASDAQ: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives today announced the acquisition of ...
eLife5d
Longitudinal tracking of neuronal activity from the same cells in the developing brain using Track2p
This important study presents a new method for longitudinally tracking cells in two-photon imaging data that addresses the specific challenges of imaging neurons in the developing cortex. It provides ...
Mirage News3d
Which Tool Tells Truth? Head-to-head Benchmarking Of ScRNA-seq CNV Methods
Tumors are often genetic mosaics, harboring diverse cell populations shaped by mutations like copy number variations (CNVs). These genomic alterations ...
Genetic 'barcode' discovery cracks the code of centromeres, the genome's most mysterious regions
When people think of DNA, they usually think of genes, the parts that code for proteins and drive inherited traits. But there ...
News-Medical.Net on MSN2d
Explainable AI helps decode the substrate specificity of γ-secretase enzyme
Using artificial intelligence, researchers show how γ-secretase recognizes substrates - an important advance for fundamental ...
News Medical on MSN3d
Chan Zuckerberg initiative unveils AI model to decode cellular behavior
Today, the Chan Zuckerberg Initiative (CZI) announced its latest AI model aimed at helping researchers better understand how cells behave by focusing on the key networks that control cell behavior, ...